Emerging targeted therapies in non-small cell lung cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–644.
   PubMed Web of Science ®Google Scholar
• Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105(9):595–605.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagnostics: JMD. 2013;15(4):415–453.
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama. 2014;311(19):1998–2006.
   PubMed Web of Science ®Google Scholar
• Lopez-Chavez A, Thomas A, Rajan A, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol: Official J Am Soc Clin Oncol. 2015;33(9):1000–1007.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol: Official J Am Soc Clin Oncol. 2011;1(26):3574–3579.
   Web of Science ®Google Scholar
• Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol: Official J Am Soc Clin Oncol. 2011;29(15):2046–2051.
   PubMed Web of Science ®Google Scholar
• Roberts P, Der C. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–3310.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
   PubMed Web of Science ®Google Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–332.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
   PubMed Web of Science ®Google Scholar
• Spagnolo F, Ghiorzo P, Orgiano L, et al BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther. 2015;8:157–168.
   PubMed Web of Science ®Google Scholar
• Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol: Official J Am Soc Clin Oncol. 2013;31(20):e341–344.
   PubMed Web of Science ®Google Scholar
• Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thoracic Oncol: Official Publication Int Assoc Study Lung Cancer. 2012;7(10):e23–24.
   PubMed Web of Science ®Google Scholar
• Robinson SD, O’Shaughnessy JA, Cowey CL, et al. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Amsterdam, Netherlands Lung Cancer. 2014;85(2):326–330.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726–736.
   PubMed Web of Science ®Google Scholar
• Planchard D, Kim T, Mazieres J, et al. LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928). Ann Oncol. 2014;25(suppl 4):mdu438. 446.
   Google Scholar
• Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Oxford, England: 1990 Eur J Cancer. 2013;49(6):1297–1304.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thoracic Oncol: Official Publication Int Assoc Study Lung Cancer. 2013;8(5):e41–42.
   PubMed Web of Science ®Google Scholar
• Gautschi O, Peters S, Zoete V, et al. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer. 2013;82(2):365–367. Amsterdam, Netherlands.
   PubMed Web of Science ®Google Scholar
• Schmid S, Siano M, Joerger M, et al. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Amsterdam, Netherlands Lung Cancer. 2015;87(1):85–87.
   PubMed Web of Science ®Google Scholar
• Cipriani NA, Abidoye OO, Vokes E, et al. MET as a target for treatment of chest tumors. Amsterdam, Netherlands Lung Cancer. 2009;63(2):169–179.
   PubMed Web of Science ®Google Scholar
• Robinson KW, Sandler AB. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist. 2013;18(2):115–122.
   PubMed Web of Science ®Google Scholar
• Gelsomino F, Facchinetti F, Haspinger E, et al. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol. 2014;89(2):284–299.
   PubMed Web of Science ®Google Scholar
• Okuda K, Sasaki H, Yukiue H, et al. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 2008;99(11):2280–2285.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol: Official J Am Soc Clin Oncol. 2009;27(10):1667–1674.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science New York, NY. 2007;316(5827):1039–1043.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
   PubMed Web of Science ®Google Scholar
• Stabile LP, Rothstein ME, Keohavong P, et al. Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice. Cancers. 2010;2(4):2153–2170.
   PubMedGoogle Scholar
• Zhang YW, Staal B, Essenburg C, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 2010;70(17):6880–6890.
   PubMed Web of Science ®Google Scholar
• Mok T, Park K, Geater S, et al. A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab, a humanized hepatocyte growth factor (HGF) inhibitory monoclonal antibody, in combination with gefitinib versus gefitinib alone in Asian patients with lung adenocarcinoma. Ann Oncol. 2012;23(9):ix391.
   Google Scholar
• Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol: Official J Am Soc Clin Oncol. 2013;31(32):4105–4114.
   PubMed Web of Science ®Google Scholar
• Spigel D, Edelman M, O’Byrne K. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC. Presentation at American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, May 30–June 3, 2014. Abstract published in J Clin Oncol: Official J Am Soc Clin Oncol. 2014;32(15):128045–128144.
   Web of Science ®Google Scholar
• Sequist LV, Von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011;29(24):3307–3315.
   PubMed Web of Science ®Google Scholar
• Camidge D, Ou S, Shapiro G, et al Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol: Official J Am Soc Clin Oncol. 2014;32:5.
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol. 2004;15(1):19–27.
   PubMed Web of Science ®Google Scholar
• Lara PN Jr., Laptalo L, Longmate J, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004;5(4):231–236.
   PubMedGoogle Scholar
• Langer CJ, Stephenson P, Thor A, et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol. 2004;22(7):1180–1187.
   PubMed Web of Science ®Google Scholar
• Zinner RG, Glisson BS, Fossella FV, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer. 2004;44(1):99–110.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
   PubMed Web of Science ®Google Scholar
• Mazieres J, Zalcman G, Crino L, et al. Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. J Clin Oncol: Official J Am Soc Clin Oncol. 2015;33(9):992–999.
   Google Scholar
• Crino L, Kim D, Riely G et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. 2011 ASCO Annual Meeting Proceedings. J Clin Oncol. 2011;29(suppl 15):7514.
   Google Scholar
• Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007;67(9):4408–4417.
   PubMed Web of Science ®Google Scholar
• Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thoracic Oncol: Official Publication Int Assoc Study Lung Cancer. 2011;6(5):942–946.
   PubMed Web of Science ®Google Scholar
• Schwab R, Petak I, Kollar M, et al. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer. 2014;83(1):109–111. Amsterdam, Netherlands.
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19(49):5548–5557.
   PubMed Web of Science ®Google Scholar
• Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795(1):37–52.
   PubMed Web of Science ®Google Scholar
• Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Research: Official J Am Assoc Cancer Research. 2012;18(17):4570–4579.
   PubMed Web of Science ®Google Scholar
• Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol: Official J Am Soc Clin Oncol. 2012;30(8):863–870.
   PubMed Web of Science ®Google Scholar
• Ou SH, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 2012;17(11):1351–1375.
   PubMed Web of Science ®Google Scholar
• Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013;368(25):2395–2401.
   PubMed Web of Science ®Google Scholar
• Davies KD, Mahale S, Astling DP, et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. Plos One. 2013;8(12):e82236.
   PubMed Web of Science ®Google Scholar
• Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol: Official J Am Soc Clin Oncol. 1999;17(1):380–393.
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355–365.
   PubMed Web of Science ®Google Scholar
• Plaza-Menacho I, Mologni L, McDonald NQ. Mechanisms of RET signaling in cancer: current and future implications for targeted therapy. Cell Signal. 2014;26(8):1743–1752.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–381.
   PubMed Web of Science ®Google Scholar
• Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382–384.
   PubMed Web of Science ®Google Scholar
• Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375–377.
   PubMed Web of Science ®Google Scholar
• Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630–635.
   PubMed Web of Science ®Google Scholar
• Gautschi O, Zander T, Keller FA, et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thoracic Oncol: Official Publication Int Assoc Study Lung Cancer. 2013;8(5):e43–44.
   PubMed Web of Science ®Google Scholar
• Falchook GS, Ordonez NG, Bastida CC, et al. Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol: Official J Am Soc Clin Oncol. 2014 Nov 3. [Epub ahead of print]. doi:10.1200/JCO.2013.50.5016.
   Google Scholar
• Wu H, Shih JY, Yang JC. Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. J Thoracic Oncol: Official Publication Int Assoc Study Lung Cancer. 2015;10(9):e95–96.
   PubMed Web of Science ®Google Scholar
• Song M. Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer. J Med Chem. 2015;58(9):3672–3681.
   Web of Science ®Google Scholar
• Yang WX, Li GD, Zhou Q, et al. [Detection of API2-MALT1 fusion gene in extranodal B-cell lymphoma and its significance.]. Zhonghua Bing Li Xue Za Zhi. 2006;35(2):92–96.
   PubMedGoogle Scholar
• Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol: Official J Am Soc Clin Oncol. 2009;27(34):5838–5847.
   PubMed Web of Science ®Google Scholar
• Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment of non-small cell lung cancer. Amsterdam, Netherlands Lung Cancer. 2015;87(3):220–225.
   PubMed Web of Science ®Google Scholar
• Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol: Official J Am Soc Clin Oncol. 2013;31(16):1997–2003.
   PubMed Web of Science ®Google Scholar
• Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol. 2010;5(12):1922–1932.
   PubMed Web of Science ®Google Scholar
• Clamon G, Herndon J, Kern J, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. 2005;103(8):1670–1675.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med. 2006;354(24):2619–2621.
   PubMed Web of Science ®Google Scholar
• Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2(10):922–933.
   PubMed Web of Science ®Google Scholar
• Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006;10(1):25–38.
   PubMed Web of Science ®Google Scholar
• De Greve J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76(1):123–127. Amsterdam, Netherlands.
   PubMed Web of Science ®Google Scholar
• Gow CH, Liao WY, Liu YN, et al. Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib. J Thoracic Oncol: Official Publication Int Assoc Study Lung Cancer. 2015;10(7):e58–60.
   PubMed Web of Science ®Google Scholar